KAPAKairos Pharma Ltd. Common Stock

0.2900USD-6.33%Mkt Cap: 6.87M $P/E:

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the tr…

Key Statistics

Company
Market Cap6.87M $
Enterprise Value4.25M $
Revenue (TTM)
Gross Profit
Net Income (TTM)-5.45M $
Revenue/Share
Last Price0.2900 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-0.43
PEG
EV/EBITDA-0.73
EV/Revenue
P/S
P/B1.48
EPS (TTM)-0.28
EPS (Forward)-0.67
52W Range
0.26951% of range2.110
52W High2.110 USD
52W Low0.2695 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-85.90%
ROA-83.29%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-3.44M $
CapEx (TTM)
FCF Margin
FCF Yield-27.47%
Net Debt-2.63M $
Net Debt/EBITDA0.45
Balance Sheet
Debt/Equity
Current Ratio11.98
Quick Ratio9.91
Book Value/Sh0.1960 USD
Cash/Share0.1110 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating
Target (Mean)7.000 USD
Upside (mean)+2313.8%
Target Range2.000 USD12.00 USD
$2.000+2313.8% to mean$12.00
# Analysts2
Ownership
Shares Out.23.70M
Float15.70M
Insiders33.61%
Institutions7.82%
Short Interest
Short Ratio0.1d
Short % Float3.55%
Short % Out.2.42%
Shares Short517.82K
Short (prev mo.)155.94K
Technical
SMA 500.3554 (-18.4%)
SMA 2000.5860 (-50.5%)
Beta
S&P 52W Chg19.18%
Avg Vol (30d)3.55M
Avg Vol (10d)343.63K
Technical Indicators
RSI (14)37.8
MACD-0.0124
MACD Signal-0.0089
MACD Hist.-0.0035
BB Upper0.3883 USD
BB Middle0.3281 USD
BB Lower0.2679 USD
BB Width36.71%
ATR (14)0.0293 USD
Vol Ratio (20d)0.18x